Can a simple drug cut blood loss in kids with CP after hip surgery?
NCT ID NCT07672158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase III trial tests whether giving tranexamic acid continuously for 24 hours after hip surgery can reduce blood loss in non-ambulatory children with cerebral palsy. About 52 children aged 4 to 16 will be randomly assigned to receive either the drug or a placebo. The goal is to see if the drug lowers the need for blood transfusions and improves recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tranexamic acid
What this could lead to
If it works, this could provide a safe way to reduce blood loss and the need for blood transfusions in children with cerebral palsy after major hip surgery.
What could go wrong
This is a small, early-stage trial with only 52 children, so results may not apply to everyone. There is also a risk of seizures, which the study will monitor closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Royal Children's Hospital
Melbourne, Victoria, 3052, Australia